United States · FDA National Drug Code directory
TAZAROTENE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 45802-436_710d0db0-54af-49fd-b2ed-77582a4b3238
- Product NDC
- 45802-436
- Form
- GEL
- Composition / generic term
- tazarotene
- Labeler
- Padagis Israel Pharmaceuticals Ltd
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20230605
- Source listing expiry
- 20261231
Source-listed ingredients
- TAZAROTENE — .5 mg/g
These values do not establish equivalence or a dose recommendation.
Packages
- 1 TUBE in 1 CARTON (45802-436-01) / 100 g in 1 TUBE · 45802-436-01
- 1 TUBE in 1 CARTON (45802-436-94) / 30 g in 1 TUBE · 45802-436-94
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →